Cronos Group Inc. operates as a cannabinoid company.
Share Price & News
How has Cronos Group's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: CRON is less volatile than 75% of Canadian stocks over the past 3 months, typically moving +/- 5% a week.
Volatility Over Time: CRON's weekly volatility (5%) has been stable over the past year.
7 Day Return
1 Year Return
Return vs Industry: CRON underperformed the Canadian Pharmaceuticals industry which returned 29.2% over the past year.
Return vs Market: CRON underperformed the Canadian Market which returned 28.9% over the past year.
Long-Term Price Volatility Vs. Market
How volatile is Cronos Group's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 month ago | Simply Wall StIs Cronos Group Inc. (TSE:CRON) Trading At A 47% Discount?
3 months ago | Simply Wall StDid Cronos Group Inc. (TSE:CRON) Insiders Sell Shares?
4 months ago | Simply Wall StWhat You Need To Know About Cronos Group Inc.'s (TSE:CRON) Investor Composition
Cronos Group Fundamentals Summary
|CRON fundamental statistics|
Is CRON overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|CRON income statement (TTM)|
|Cost of Revenue||US$91.82m|
Last Reported Earnings
Jun 30, 2021
Next Earnings Date
|Earnings per share (EPS)||-0.40|
|Net Profit Margin||-256.50%|
How did CRON perform over the long term?See historical performance and comparison
Is Cronos Group undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: CRON (CA$7.59) is trading below our estimate of fair value (CA$30.05)
Significantly Below Fair Value: CRON is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: CRON is unprofitable, so we can't compare its PE Ratio to the Canadian Pharmaceuticals industry average.
PE vs Market: CRON is unprofitable, so we can't compare its PE Ratio to the Canadian market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate CRON's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: CRON is good value based on its PB Ratio (1.4x) compared to the CA Pharmaceuticals industry average (2.6x).
How is Cronos Group forecast to perform in the next 1 to 3 years based on estimates from 12 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: CRON is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (1.5%).
Earnings vs Market: CRON is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: CRON's is expected to become profitable in the next 3 years.
Revenue vs Market: CRON's revenue (46.3% per year) is forecast to grow faster than the Canadian market (6.2% per year).
High Growth Revenue: CRON's revenue (46.3% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: CRON is forecast to be unprofitable in 3 years.
How has Cronos Group performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: CRON is currently unprofitable.
Growing Profit Margin: CRON is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: CRON is unprofitable, but has reduced losses over the past 5 years at a rate of 28.1% per year.
Accelerating Growth: Unable to compare CRON's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: CRON is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (115.1%).
Return on Equity
High ROE: CRON has a negative Return on Equity (-9.01%), as it is currently unprofitable.
How is Cronos Group's financial position?
Financial Position Analysis
Short Term Liabilities: CRON's short term assets ($1.2B) exceed its short term liabilities ($200.6M).
Long Term Liabilities: CRON's short term assets ($1.2B) exceed its long term liabilities ($8.1M).
Debt to Equity History and Analysis
Debt Level: CRON is debt free.
Reducing Debt: CRON has no debt compared to 5 years ago when its debt to equity ratio was 1%.
Debt Coverage: CRON has no debt, therefore it does not need to be covered by operating cash flow.
Interest Coverage: CRON has no debt, therefore coverage of interest payments is not a concern.
What is Cronos Group current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate CRON's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate CRON's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if CRON's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if CRON's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of CRON's dividend in 3 years as they are not forecast to pay a notable one for the Canadian market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Kurt Schmidt (64 yo)
Mr. Kurt Thomas Schmidt, B.Sc., MBA, serves as the President and Chief Executive Officer of Cronos Group Inc. since September 9, 2020. He has been an Independent Director of Campbell Soup Company since Nov...
CEO Compensation Analysis
Compensation vs Market: Kurt's total compensation ($USD10.12M) is above average for companies of similar size in the Canadian market ($USD1.93M).
Compensation vs Earnings: Insufficient data to compare Kurt's compensation with company performance.
Experienced Management: CRON's management team is not considered experienced ( 1.3 years average tenure), which suggests a new team.
Experienced Board: CRON's board of directors are not considered experienced ( 2.6 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 6.7%.
Cronos Group Inc.'s company bio, employee growth, exchange listings and data sources
- Name: Cronos Group Inc.
- Ticker: CRON
- Exchange: TSX
- Founded: 2012
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: CA$2.833b
- Shares outstanding: 373.27m
- Website: https://www.thecronosgroup.com
Number of Employees
- Cronos Group Inc.
- 111 Peter Street
- Suite 300
- M5V 2H1
Cronos Group Inc. operates as a cannabinoid company. It manufactures, markets, and distributes hemp-derived supplements and cosmetic products through e-commerce, retail, and hospitality partner channels un...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/09/19 22:11|
|End of Day Share Price||2021/09/17 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.